FIELD: chemistry.
SUBSTANCE: invention relates to novel compounds of formula (I) or pharmaceutically acceptable salts thereof 
where R1 and R2 together denote a group selected form groups of formula (III-1): 
, where R9 denotes 1) a lower alkyl group, optionally substituted with a halogen atom or lower alkoxy group, 2) an aryl group, 3) an aralkyl group, 4) a heteroarylalkyl group, 5) a heteroaryl group, where the aryl, aralkyl, heteroarylalkyl and heteroaryl groups can be substituted with a halogen atom, lower alkyl group, optionally substituted with a lower alkoxy group or 1-3 halogen atoms, lower alkoxy group, optionally substituted with 1-3 halogen atoms, cyano group, hydroxy group, alkylsulphonyl group, cycloalkylsulphonyl group, aryl group, heteroaryl group, alkylaminocarbonyl group, alkanoyl amino group, alkyl amino group or dialkylamino group; R10 denotes a lower alkyl group, optionally substituted with 1-3 halogen atoms, or a lower alkylsulphonyl group; X9-X12 denotes a carbon atom or a nitrogen atom, where the carbon atom can be independently substituted with a lower alkyl group, optionally substituted with a halogen atom or a lower alkoxy group, lower alkoxy group, optionally substituted with a halogen atom, or a cyano group or a halogen atom; R3 denotes a) a group of formula (II-1): 
(ii-U where R4 and R5, taken together with a nitrogen atom, form a 5- or 6-member monocyclic ring, where the monocyclic ring may contain a substitute in form of a lower alkyl group, m1 equals 3; or b) a group of formula (II-2): 
, where R6 denotes a lower alkyl group or cycloalkyl group; m2 equals 1 or 2; X1-X4 all denote carbon atoms, or one of X1-X4 denotes a nitrogen atom and the rest denote carbon atoms; and where "heteroaryl" in each case relates to a 5- or 6-member aromatic ring containing 1-3 heteroatoms selected from a nitrogen atom, oxygen atom and a sulphur atom. The invention also relates to a histamine H3 receptor antagonist or inverse agonist, as well as a preventive or medicinal agent.
EFFECT: obtaining novel biologically active compounds, having histamine H3 receptor antagonist or inverse agonist activity.
11 cl, 8 ex, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| CONDENSED 4-OXOPYRIMIDINE DERIVATIVE | 2005 |
|
RU2358969C2 |
| HETEROCYCLIC SPIRO COMPOUNDS AS MAGL INHIBITORS | 2018 |
|
RU2726631C1 |
| SPIRO-FUSED PIPERIDINE DERIVATIVES FOR APPLICATION AS INHIBITORS OF EXTERNAL MEDULLAR LAYER POTASSIUM CHANNEL | 2013 |
|
RU2642066C2 |
| SPIROCYCLIC NITRILES AS PROTEASE INHIBITORS | 2007 |
|
RU2478620C2 |
| SPIROAZACYCLIC COMPOUNDS, METHOD FOR INHIBITION IF ACTIVITY OR ACTIVATION OF SEROTONIN 5-НТ2А RECEPTOR, METHOD FOR TREATMENT OF MORBID STATE ASSOCIATED WITH SEROTONIN 5-НТ2А RECEPTOR AND THEIR USING | 2002 |
|
RU2315051C2 |
| SPIROCYCLIC NITRILES AS PROTEASE INHIBITORS | 2012 |
|
RU2621695C2 |
| AROMATIC 6,7-DISUBSTITUTED 3-QUINOLINECARBOXAMIDE DERIVATIVES, METHOD FOR PRODUCTION THEREOF (VARIANTS), PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AND USE THEREOF IN DRUG MANUFACTURING | 2002 |
|
RU2281940C2 |
| PHENYLPYRAZOL DERIVATIVES | 2008 |
|
RU2480456C2 |
| PHARMACEUTICALLY ACTIVE COMPOUNDS AS Axl INHIBITORS | 2011 |
|
RU2573834C2 |
| AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS | 2015 |
|
RU2683309C2 |
